Cost-effectiveness of dabigatran versus vitamin K antagonists for the prevention of stroke in patients with atrial fibrillation: A French payer perspective
- Chevalier, Julie
- Delaitre, Olivier
- Hammès, Florence
- de Pouvourville, Gérard
DOIAbstract
SummaryBackgroundAtrial fibrillation is the main cause of stroke, but the risk can be reduced, usually with vitamin K antagonists (VKAs) such as warfarin. The RE-LY atrial fibrillation study demonstrated that the rates of stroke and systemic embolism with dabigatran (an oral direct thrombin inhibitor) were similar to or lower than those with warfarin.AimsTo estimate the cost-effectiveness, from a French payer perspective, of dabigatran (150 or 110mg bid for patients<or≥80 years, respectively) versus warfarin.MethodsCost-effectiveness was modeled using a Markov model in a cohort of 10,000 patients with atrial fibrillation followed over their lifetime. Events accounted for included ischemic stroke, systemic embolism, transient ischemic attack...
Add to ORKG